Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

NAMS 2018 Utian Translational Science Symposium, October 2018, San Diego, California New therapies for leiomyomas

when surgery may not be the best option

doi: 10.1097/GME.0000000000001402
NAMS Translational Science Symposium Report
Buy

The North American Menopause Society (NAMS) held the 2018 Utian Translational Science Symposium on October 2, 2018, in San Diego, California, to discuss new therapeutic approaches to uterine leiomyomas when surgery is not the optimal choice.

Uterine leiomyomas arise from a single clonal cell and are the most common gynecologic disorder affecting reproductive and perimenopausal women worldwide. The prevalence of this disorder is approximately 40% to 70% in white women and 60% to 80% in black women. Recent research suggests that both estrogen and progesterone modulate the growth of leiomyomas, with progesterone being a major stimulator of leiomyoma growth.

Women with symptomatic uterine leiomyomas experience heavy uterine bleeding, bulk symptoms, miscarriages, and pregnancy complications. Surgical therapies such as myomectomy or hysterectomy are highly effective; however, medical therapy with progestin-predominant contraceptives or gonadotropin-releasing hormone (GnRH) agonists are in many ways inadequate to address the unmet need for better, noninvasive, and cost-effective treatments.

Recent advances in medical treatment, such as selective progesterone receptor modulators, new oral GnRH analogs, and clinical trials that provide new therapeutic approaches, were presented by speakers at the symposium. Research on why there is a prevalence of leiomyomas in black women, the racial and genetic effects on leiomyoma growth, and potential molecular mechanisms also were discussed.

Address correspondence to: The North American Menopause Society, 30100 Chagrin Blvd. Suite 210; Pepper Pike, OH 44124. E-mail: info@menopause.org

Received 28 June, 2019

Revised 28 June, 2019

Accepted 28 June, 2019

This report was developed by The North American Menopause Society based on the presentations of the speakers at the 2018 Utian Translational Science Symposium consisting of Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP; William Catherino, MD, PhD; James H. Liu, MD, NCMP; Nanette F. Santoro, MD; Elizabeth A. Stewart, MD; and Wendy L. Wolfman, MD, FRCS(C), FACOG, NCMP.

Financial disclosure/conflicts of interest: Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, reports: Speakers Bureau: AbbVie, Allergan, Bayer, Myovant. William Catherino, MD, PhD reports: Consultant/Advisory Board: AbbVie, Allergan, Bayer; Grant/Research Support: Allergan; Employment (Spouse): Serono. James H. Liu, MD, NCMP, reports: Consultant/Advisory Board: Allergan, Ascend, TherapeuticsMD; Grant/Research Support: AbbVie, Bayer, Ferring, Palatin (all funds paid to institution). JoAnn V. Pinkerton, MD, NCMP, reports no relevant financial relationships. Nanette F. Santoro, MD, reports: Consultant/Advisory Board: Ogeda/Astellas; Stock/Ownership: Menogenix. Elizabeth A. Stewart, MD, reports: Consultant/Advisory Board: AbbVie, Bayer, Myovant. Wulf H. Utian, MD, PhD, DSC(Med), FRCOG, FACOG, FICS, reports: Consultant/Advisory Board: Endoceutics, Mithra, Pharmavite, PulseNMore. Wendy L. Wolfman, MD, FRCS(C), FACOG, NCMP, reports: Consultant/Advisory Board: Acerus, Pfizer; Speakers Bureau: Merck, Pfizer, Searchlight; Grant/Research Support: Pfizer.

Funding/support: The 2018 Utian Translational Science Symposium was supported by grant funding from Allergan.

Online date: August 23, 2019

© 2019 by The North American Menopause Society.